Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Psychedelics Therapeutics
|
| gptkbp:CEO |
Florian_Brand
|
| gptkbp:clinicalTrials |
anxiety
depression Phase 1 Phase 2 PTSD substance use disorders psychedelic compounds |
| gptkbp:collaborations |
gptkb:Imperial_College_London
gptkb:Johns_Hopkins_University gptkb:University_of_California,_San_Francisco gptkb:Heffter_Research_Institute MAPS Multidisciplinary_Association_for_Psychedelic_Studies |
| gptkbp:focus |
psychedelic therapies
|
| gptkbp:founded |
2020
|
| gptkbp:founder |
gptkb:Christian_Angermayer
|
| gptkbp:funding |
$125 million
Series B |
| gptkbp:headquarters |
gptkb:Berlin,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Atai Life Sciences
|
| gptkbp:investmentFocus |
biotechnology
psychedelic research mental health innovations psychedelic startups |
| gptkbp:mission |
transform mental health treatment
|
| gptkbp:partnerships |
Compass Pathways
DemeRx Kriya_Therapeutics |
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:research_areas |
mental health
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
ATAI
|
| gptkbp:subsidiary |
Atai_Life_Sciences_GmbH
Atai_Life_Sciences_US |
| gptkbp:supplyChain |
AT-001
AT-002 AT-003 AT-004 AT-005 AT-006 AT-007 AT-008 AT-009 AT-010 GRX-917 KET-01 PCN-101 |
| gptkbp:technology |
psychedelic-assisted therapy
|
| gptkbp:website |
www.atai.life
|